Komori
Occurring Fact4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Our Views on the Report Concerning Our Company, “Part II - CiRA, Dr. Yamanaka, and the Undisclosed History of Image Duplication Concerns”

The Company presented its rebuttal and views on the report concerning Amchepri and other matters published by Gotham City Research LLC. It explained the reliability of the approval application materials for Amchepri and the regulatory authorities' review record, and outlined its policy of continuing the trials and taking legal action as necessary.

Worth reading
—
Scored from 0 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-08-12
What was corrected and how
ItemDetails
Items this document does not state (6)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company stated that GCR's report is unacceptable because it is based on one-sided views and assertions. It also explained its views after confirming the reliability of the approval review materials for Amchepri and noting that approval was obtained following scientific and medical review and investigation by the regulatory authorities.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Our Views on the Report Concerning Our Company, “Part II - CiRA, Dr. Yamanaka, and the Undisclosed History of Image Duplication Concerns” | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori